We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+0.32%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$5.94B
AUM Growth
-$751M
Cap. Flow
-$607M
Cap. Flow %
-10.22%
Top 10 Hldgs %
40.52%
Holding
146
New
24
Increased
39
Reduced
15
Closed
40

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$179M
2
ALIT icon
Alight
ALIT
+$88M
3
XYZ
Block Inc
XYZ
+$77.8M
4
TWLO icon
Twilio
TWLO
+$73.7M
5
WRBY icon
Warby Parker
WRBY
+$53.8M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$269M
2
UBER icon
Uber
UBER
+$193M
3
META icon
Meta Platforms (Facebook)
META
+$161M
4
PSFE icon
Paysafe
PSFE
+$156M
5
AAPL icon
Apple
AAPL
+$99.6M

Sector Composition

Rank Sector Weight
1 Healthcare 32.32%
2 Consumer Discretionary 19.04%
3 Technology 18.49%
4 Industrials 18.23%
5 Financials 4.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
26
Natera
NTRA
$45.4B
$83.3M 1.4%
747,220
+393,520
+111% +$45.1M
TEL icon
27
TE Connectivity
TEL
$62.7B
$82.9M 1.4%
603,877
-650
-0.1% -$93.8K
ADI icon
28
Analog Devices
ADI
$191B
$80M 1.35%
477,645
+166,005
+53% +$27.8M
HWM icon
29
Howmet Aerospace
HWM
$114B
$79.6M 1.34%
2,551,230
+890,430
+54% +$28.7M
XYZ
30
Block Inc
XYZ
$47.2B
$72.7M 1.22%
+302,930
New +$77.8M
AGIO icon
31
Agios Pharmaceuticals
AGIO
$1.9B
$60.5M 1.02%
1,311,748
+324,292
+33% +$15.7M
MA icon
32
CALL
Mastercard
MA
$494B
$60M 1.01%
+172,600
New +$62.8M
RPRX icon
33
Royalty Pharma
RPRX
$25.3B
$55.2M 0.93%
1,527,900
+798,523
+109% +$31M
FULC icon
34
Fulcrum Therapeutics
FULC
$294M
$54.8M 0.92%
1,941,969
+314,525
+19% +$5.96M
WRBY icon
35
Warby Parker
WRBY
$3.23B
$53M 0.89%
+1,000,000
New +$53.8M
NXPI icon
36
NXP Semiconductors
NXPI
$60.4B
$50.2M 0.85%
256,438
-147,990
-37% -$30.7M
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$46.7M 0.79%
1,251,946
+213,176
+21% +$7.41M
KURA icon
38
Kura Oncology
KURA
$842M
$46.1M 0.78%
2,460,202
+801,496
+48% +$15.1M
STRO icon
39
Sutro Biopharma
STRO
$416M
$42.2M 0.71%
223,370
+51,832
+30% +$9.86M
ESTC icon
40
Elastic
ESTC
$7.81B
$40.4M 0.68%
+271,000
New +$41.7M
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$33.8M 0.57%
191,308
+42,436
+29% +$6.83M
ARNA
42
DELISTED
Arena Pharmaceuticals Inc
ARNA
$30.2M 0.51%
+507,088
New +$30M
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$29.3M 0.49%
862,126
+209,491
+32% +$6.69M
INSM icon
44
Insmed
INSM
$28.1B
$27.5M 0.46%
998,732
+557,667
+126% +$14.6M
KALV
45
DELISTED
KalVista Pharmaceuticals
KALV
$26.9M 0.45%
1,543,284
+352,183
+30% +$7.14M
MRNS
46
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$25M 0.42%
2,197,426
+370,981
+20% +$5.1M
MREO
47
Mereo BioPharma
MREO
$47.9M
$22.1M 0.37%
9,142,067
+492,767
+6% +$1.3M
TE
48
T1 Energy
TE
$1.65B
$20.7M 0.35%
+2,093,710
New +$19.3M
EYPT icon
49
EyePoint Inc
EYPT
$1.18B
$17.8M 0.3%
1,704,589
+326,257
+24% +$3.11M
XENE icon
50
Xenon Pharmaceuticals
XENE
$6.12B
$17.7M 0.3%
1,158,961
+564,850
+95% +$9.82M
1
2
3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Suvretta Capital Management held 146 positions worth $5.94B, down 11% from $6.69B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Suvretta Capital Management withdrew a net $607M in Q3 2021, closing 40 positions and reducing 15 holdings. Its most notable exit was Alphabet (Google) Class C, an estimated $269M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Suvretta Capital Management opened a new position in Thermo Fisher Scientific worth $186M.

  • Suvretta Capital Management's largest Q3 2021 buy was Thermo Fisher Scientific: 325,810 shares worth $186M.
  • Suvretta Capital Management added most to Twilio in Q3 2021, an estimated $73.7M increase.
  • Suvretta Capital Management's biggest Q3 2021 reduction was Medtronic, cutting an estimated $50.1M.
  • Suvretta Capital Management fully exited Alphabet (Google) Class C in Q3 2021, selling an estimated $269M.
  • Suvretta Capital Management's ten largest holdings make up 41% of its $5.94B portfolio in Q3 2021.
  • Suvretta Capital Management opened 24 new positions and closed 40 in Q3 2021.
  • Suvretta Capital Management's portfolio value fell 11% quarter-over-quarter to $5.94B.

Based on Suvretta Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.